Advertisement
News
Advertisement

InVivo seeks FDA humanitarian use exemption for its spinal scaffold

Mon, 12/17/2012 - 5:00pm
Mass Device

InVivo Therapeutics seeks FDA humanitarian use device exemption for its biopolymer scaffolding product in treatment of non-severing spinal cord injuries.

invivo logo

InVivo Therapeutics (OTC:NVIV) is seeking FDA approval for a humanitarian use device designation for its biopolymer scaffolding product in treatment of traumatic spinal cord injuries.

The Cambridge, Mass.-based firm expects to begin a clinical trial of the scaffolding in acute spinal cord injuries early next year.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading